Zobrazeno 1 - 10
of 196
pro vyhledávání: '"Jessica J. Lin"'
Autor:
Justin M. Cheung, MD, Jiyoon Kang, DO, Beow Y. Yeap, ScD, Jennifer L. Peterson, BS, Andrew Do, BS, Justin F. Gainor, MD, Subba R. Digumarthy, MD, Jessica J. Lin, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100645- (2024)
Introduction: Central nervous system (CNS) metastases remain a common challenge in patients with ALK-positive NSCLC. We previously reported reinduction of CNS responses using dose-intensified alectinib in two patients with CNS progression on standard
Externí odkaz:
https://doaj.org/article/4045a802fb364d54add361b8d80efe2a
Autor:
Jaime L. Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R. Digumarthy, Andrew Do, Audrey Liu, Justin F. Gainor, Jochen K. Lennerz, Timothy F. Burns, Jessica J. Lin
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-7 (2023)
Abstract Acquired drug resistance remains a major problem across oncogene-addicted cancers. Elucidation of mechanisms of resistance can inform rational treatment strategies for patients relapsing on targeted therapies while offering insights into tum
Externí odkaz:
https://doaj.org/article/39fd463012fa4aa7af342003242f7782
Autor:
Ibiayi Dagogo-Jack, MD, Lesli A. Kiedrowski, MS, MPH, Rebecca S. Heist, MD, MPH, Jessica J. Lin, MD, Catherine B. Meador, MD, PhD, Elizabeth A. Krueger, NP, Andrew Do, BS, Jennifer Peterson, BS, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jochen K. Lennerz, MD, PhD, Subba R. Digumarthy, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100534- (2023)
Introduction: MET amplification is a potentially actionable resistance mechanism in ALK-rearranged (ALK+) lung cancer. Studies describing treatment outcomes of this molecular subgroup are lacking. Methods: We assembled a cohort of patients with ALK+
Externí odkaz:
https://doaj.org/article/48f3d6a56b8d4f66bc9f438add97a0a8
Autor:
Qing Zhang, PhD, Jessica J. Lin, MD, Navdeep Pal, M.B.B.S., MPH, Letizia Polito, PhD, Huong Trinh, MD, Magalie Hilton, MSc, Vlatka Smoljanović, MD, Nino Kurtsikidze, MD, Venice Archer, MD, Matthew G. Krebs, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100483- (2023)
Introduction: Alectinib was found to have superior efficacy to crizotinib in the phase 3 ALEX study and is a preferred initial treatment for patients with advanced ALK-positive NSCLC. To understand the efficacy of alectinib in U.S. clinical practice,
Externí odkaz:
https://doaj.org/article/ffc18652305b4b43b4d78d33116f2326
Autor:
Alissa J. Cooper, MD, Alona Muzikansky, MA, Jochen Lennerz, MD, PhD, Farhaana Narinesingh, M.B.B.S., Mari Mino-Kenudson, MD, Yin P. Hung, MD, PhD, Zofia Piotrowska, MD, MHS, Ibiayi Dagogo-Jack, MD, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jessica J. Lin, MD, Rebecca S. Heist, MD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100390- (2022)
Introduction: Co-occurring mutations in KRAS-mutant NSCLC are associated with discrete biological properties and modulate therapeutic susceptibilities. As G12D-specific inhibitors are expected to enter the clinic, we sought to investigate the charact
Externí odkaz:
https://doaj.org/article/b74d2bef942c4556b6ea5685e2ff735a
Autor:
Jaime L. Schneider, MD, PhD, Alona Muzikansky, MA, Jessica J. Lin, MD, Elizabeth A. Krueger, NP, Inga T. Lennes, MD, Joseph O. Jacobson, MD, Michael Cheng, MD, Rebecca S. Heist, MD, MPH, Zofia Piotrowska, MD, MHS, Justin F. Gainor, MD, Alice T. Shaw, MD, PhD, Ibiayi Dagogo-Jack, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100347- (2022)
Introduction: The central nervous system (CNS) is a common site of progression among patients with ROS1-rearranged lung cancer receiving crizotinib. We conducted a phase 2 study to evaluate the intracranial efficacy of lorlatinib in patients with ROS
Externí odkaz:
https://doaj.org/article/93980cd67c144363bbe8189dbeede26f
Autor:
Joao V. Alessi, Arielle Elkrief, Biagio Ricciuti, Xinan Wang, Alessio Cortellini, Victor R. Vaz, Giuseppe Lamberti, Rosa L. Frias, Deepti Venkatraman, Claudia A.M. Fulgenzi, Federica Pecci, Gonzalo Recondo, Alessandro Di Federico, Adriana Barrichello, Hyesun Park, Mizuki Nishino, Grace M. Hambelton, Jacklynn V. Egger, Marc Ladanyi, Subba Digumarthy, Bruce E. Johnson, David C. Christiani, Xihong Lin, Justin F. Gainor, Jessica J. Lin, David J. Pinato, Adam J. Schoenfeld, Mark M. Awad
Publikováno v:
Journal of Thoracic Oncology. 18:731-743
Autor:
Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw, Rebecca J. Nagy
Publikováno v:
Experimental Hematology & Oncology, Vol 8, Iss 1, Pp 1-6 (2019)
Abstract Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent m
Externí odkaz:
https://doaj.org/article/a2642d01b2c14be0a9b216a7597b136a
Autor:
James Lindsay, Mizuki Nishino, Biagio Ricciuti, Mark M. Awad, Joao V Alessi, Bijaya Sharma, Kathleen Pfaff, Kristen D Felt, Stephanie L Alden, Arrien A Bertram, Jessica J Lin, Mustafa Sakhi, Victor R Vaz, Madison M Turner, Scott J. Rodig, Justin F. Gainor
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/df45c1dc462e495da677e1986b11220f
Publikováno v:
Nature Cancer. 4:330-343